SPRED2 expression positively correlated with distant metastasis-free survival (DMFS) in all BC patients, suggesting that SPRED2 might affect the metastatic capacity of BC tumors regardless of ERα status (Figure S1G–I). Here, SPRED2 is linked to breast cancer.